Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.

Annals of internal medicine ·Vol. 146 ·No. 6 ·2007-03-20 ·Pages 461-3

Nathan DM, Berkwits M

Abstract

暂无摘要

MeSH Terms

Angiotensin-Converting Enzyme Inhibitors/therapeutic use Diabetes Mellitus, Type 2/prevention & control Humans Hypoglycemic Agents/therapeutic use Middle Aged Ramipril/adverse effects,therapeutic use Randomized Controlled Trials as Topic/standards Rosiglitazone Thiazolidinediones/adverse effects,therapeutic use

Chemicals

Angiotensin-Converting Enzyme Inhibitors Hypoglycemic Agents Thiazolidinediones Rosiglitazone Ramipril

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Nathan David M

Berkwits Michael

Article Info

Journal

Annals of internal medicine

Abbr.

Ann Intern Med

ISSN

1539-3704

DOI

10.7326/0003-4819-146-6-200703200-00015

Published

2007-03-20

Pages

461-3

Language

English

Region

United States

NLM ID

0372351

Subset

External Links

PubMed source DOI: 10.7326/0003-4819-146-6-200703200-00015 View journal details

Analysis Services

Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.

Contact

WeChat Official Account